*Department of Therapeutic Radiology

¶Department of Pathology, Yale School of Medicine, New Haven, CT

†Sema4, 333 Ludlow Street, Stamford, CT

‡Department of Radiation Oncology, City of Hope, Duarte, CA

§Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX

∥Division of Radiation Oncology, University of Vermont Larner College of Medicine, Burlington, VT

This publication was made possible by the Yale School of Medicine Fellowship for Medical Student Research (recipient: N.A. Saeed)—This entity had no influence in the design of the present study, the analysis, or the reporting of the results.

N.A.S.: Yale School of Medicine Fellowship for Medical Student Research. L.J.: Full-time employee at Sema4. R.H.D.: Merck and Co., Inc (Research grants, advisory board); AstraZeneca (consultant, travel expenses, speaker’s bureau, advisory board); Regeneron (consultant, travel expenses, advisory board); Novocure (advisory board); Physician Education Resource (Honoraria, travel expenses); PeerView (Honoraria, travel expenses). H.S.P.: AstraZeneca (consultant); Bristol Myers Squibb (honoraria, speaking fees); Galera Therapeutics (advisory board); Guidepoint (consultant); Grand Rounds Health (consultant); RefleXion Medical (research funding); Varian Medical Systems (honoraria, speaking fees). The remaining authors declare no conflicts of interest.

Correspondence: Henry S. Park, MD, MPH, Department of Therapeutic Radiology, Yale School of Medicine, 35 Park Street, Lower Level 513, New Haven, CT 06511. E-mail: [email protected].

Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.amjclinicaloncology.com.